BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 28555079)

  • 21. Enhanced Anti-Leukemic Effects through Induction of Immunomodulating Microenvironment by Blocking CXCR4 and PD-L1 in an AML Mouse Model.
    Hwang HS; Han AR; Lee JY; Park GS; Min WS; Kim HJ
    Immunol Invest; 2019 Jan; 48(1):96-105. PubMed ID: 30204524
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia.
    Pyzer AR; Stroopinsky D; Rajabi H; Washington A; Tagde A; Coll M; Fung J; Bryant MP; Cole L; Palmer K; Somaiya P; Karp Leaf R; Nahas M; Apel A; Jain S; McMasters M; Mendez L; Levine J; Joyce R; Arnason J; Pandolfi PP; Kufe D; Rosenblatt J; Avigan D
    Blood; 2017 Mar; 129(13):1791-1801. PubMed ID: 28126925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation of the MIR155 host gene in physiological and pathological processes.
    Elton TS; Selemon H; Elton SM; Parinandi NL
    Gene; 2013 Dec; 532(1):1-12. PubMed ID: 23246696
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute myeloid leukemia with translocation (8;16)(p11;p13) and MYST3-CREBBP rearrangement harbors a distinctive microRNA signature targeting RET proto-oncogene.
    Díaz-Beyá M; Navarro A; Ferrer G; Díaz T; Gel B; Camós M; Pratcorona M; Torrebadell M; Rozman M; Colomer D; Monzo M; Esteve J
    Leukemia; 2013 Mar; 27(3):595-603. PubMed ID: 23022987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PD-L1 siRNA-mediated silencing in acute myeloid leukemia enhances anti-leukemic T cell reactivity.
    van Ens D; Mousset CM; Hutten TJA; van der Waart AB; Campillo-Davo D; van der Heijden S; Vodegel D; Fredrix H; Woestenenk R; Parga-Vidal L; Jansen JH; Schaap NPM; Lion E; Dolstra H; Hobo W
    Bone Marrow Transplant; 2020 Dec; 55(12):2308-2318. PubMed ID: 32528120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hsa_circ_0020397 regulates colorectal cancer cell viability, apoptosis and invasion by promoting the expression of the miR-138 targets TERT and PD-L1.
    Zhang XL; Xu LL; Wang F
    Cell Biol Int; 2017 Sep; 41(9):1056-1064. PubMed ID: 28707774
    [TBL] [Abstract][Full Text] [Related]  

  • 27. miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint.
    Xu S; Tao Z; Hai B; Liang H; Shi Y; Wang T; Song W; Chen Y; OuYang J; Chen J; Kong F; Dong Y; Jiang SW; Li W; Wang P; Yuan Z; Wan X; Wang C; Li W; Zhang X; Chen K
    Nat Commun; 2016 May; 7():11406. PubMed ID: 27147225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MUC1 regulates expression of multiple microRNAs involved in pancreatic tumor progression, including the miR-200c/141 cluster.
    Mohr AM; Bailey JM; Lewallen ME; Liu X; Radhakrishnan P; Yu F; Tapprich W; Hollingsworth MA
    PLoS One; 2013; 8(10):e73306. PubMed ID: 24143167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Polysaccharide of Atractylodis Macrocephalae Rhizoma inhibits expression of immune checkpoint PD-L1 by targeting miR-34a in esophageal carcinoma cells].
    Han YC; Chen YL; Fan XQ; Shang YW; Chen X; Wang G; Shi B; Gao QL
    Zhongguo Zhong Yao Za Zhi; 2022 Mar; 47(6):1658-1665. PubMed ID: 35347965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral squamous cell carcinoma suppressed antitumor immunity through induction of PD-L1 expression on tumor-associated macrophages.
    Jiang C; Yuan F; Wang J; Wu L
    Immunobiology; 2017 Apr; 222(4):651-657. PubMed ID: 28017495
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deep Downregulation of PD-L1 by Caged Peptide-Conjugated AIEgen/miR-140 Nanoparticles for Enhanced Immunotherapy.
    Dai J; Hu JJ; Dong X; Chen B; Dong X; Liu R; Xia F; Lou X
    Angew Chem Int Ed Engl; 2022 Apr; 61(18):e202117798. PubMed ID: 35224832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia.
    Fischer J; Rossetti S; Datta A; Eng K; Beghini A; Sacchi N
    Mol Cancer; 2015 Jan; 14():7. PubMed ID: 25612891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells.
    Prima V; Kaliberova LN; Kaliberov S; Curiel DT; Kusmartsev S
    Proc Natl Acad Sci U S A; 2017 Jan; 114(5):1117-1122. PubMed ID: 28096371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inflammatory cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cells.
    Wang X; Yang L; Huang F; Zhang Q; Liu S; Ma L; You Z
    Immunol Lett; 2017 Apr; 184():7-14. PubMed ID: 28223102
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MUC1-C activates BMI1 in human cancer cells.
    Hiraki M; Maeda T; Bouillez A; Alam M; Tagde A; Hinohara K; Suzuki Y; Markert T; Miyo M; Komura K; Ahmad R; Rajabi H; Kufe D
    Oncogene; 2017 May; 36(20):2791-2801. PubMed ID: 27893710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemia.
    Huang X; Schwind S; Santhanam R; Eisfeld AK; Chiang CL; Lankenau M; Yu B; Hoellerbauer P; Jin Y; Tarighat SS; Khalife J; Walker A; Perrotti D; Bloomfield CD; Wang H; Lee RJ; Lee LJ; Marcucci G
    Oncotarget; 2016 Sep; 7(37):59273-59286. PubMed ID: 27517749
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MicroRNA 10b promotes abnormal expression of the proto-oncogene c-Jun in metastatic breast cancer cells.
    Knirsh R; Ben-Dror I; Modai S; Shomron N; Vardimon L
    Oncotarget; 2016 Sep; 7(37):59932-59944. PubMed ID: 27494896
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment.
    Krönig H; Kremmler L; Haller B; Englert C; Peschel C; Andreesen R; Blank CU
    Eur J Haematol; 2014 Mar; 92(3):195-203. PubMed ID: 24175978
    [TBL] [Abstract][Full Text] [Related]  

  • 39. miR-21 depletion in macrophages promotes tumoricidal polarization and enhances PD-1 immunotherapy.
    Xi J; Huang Q; Wang L; Ma X; Deng Q; Kumar M; Zhou Z; Li L; Zeng Z; Young KH; Zhang M; Li Y
    Oncogene; 2018 Jun; 37(23):3151-3165. PubMed ID: 29540832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Novel miRNAs as Potential Regulators of PD-1/PD-L1 Immune Checkpoint, and Prognostic Value of MIR9-1 and MIR124-2 Methylation in Ovarian Cancer].
    Kushlinskii NE; Loginov VI; Utkin DO; Filippova EA; Burdennyy AM; Korotkova EA; Pronina IV; Lukina SS; Smirnova AV; Gershtein ES; Braga EA
    Mol Biol (Mosk); 2020; 54(6):990-996. PubMed ID: 33276362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.